Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
Status:
Completed
Trial end date:
2007-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an
investigational product) is safe and relieves symptoms of HAE in patients suffering from
moderate to severe acute attacks of HAE.